CR20130059A - Procedimiento para preparar formas enantioméricas de derivados de ácido 2,3-diaminopropiónico - Google Patents

Procedimiento para preparar formas enantioméricas de derivados de ácido 2,3-diaminopropiónico

Info

Publication number
CR20130059A
CR20130059A CR20130059A CR20130059A CR20130059A CR 20130059 A CR20130059 A CR 20130059A CR 20130059 A CR20130059 A CR 20130059A CR 20130059 A CR20130059 A CR 20130059A CR 20130059 A CR20130059 A CR 20130059A
Authority
CR
Costa Rica
Prior art keywords
acid derivatives
procedure
diaminopropionic acid
enantiomeric forms
prepare
Prior art date
Application number
CR20130059A
Other languages
English (en)
Inventor
Claus-Dieter Graf
Joerg Rieke-Zapp
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43598042&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CR20130059(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of CR20130059A publication Critical patent/CR20130059A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/73—Unsubstituted amino or imino radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Pyridine Compounds (AREA)

Abstract

La invención se refiere a un procedimiento para preparar lasformas enantioméricas de derivados de ácido 2,3-diaminopropiónico de fórmula (I), en donde R1, R2 y R3 están definidos como en las reivindicaciones, por resolución de racemato.
CR20130059A 2010-08-12 2013-02-11 Procedimiento para preparar formas enantioméricas de derivados de ácido 2,3-diaminopropiónico CR20130059A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP10305884 2010-08-12
US201161428336P 2011-12-30 2011-12-30

Publications (1)

Publication Number Publication Date
CR20130059A true CR20130059A (es) 2013-03-25

Family

ID=43598042

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20130059A CR20130059A (es) 2010-08-12 2013-02-11 Procedimiento para preparar formas enantioméricas de derivados de ácido 2,3-diaminopropiónico

Country Status (23)

Country Link
US (2) US8877926B2 (es)
EP (1) EP2603491B1 (es)
JP (1) JP6000248B2 (es)
KR (1) KR20130099044A (es)
CN (1) CN103209961A (es)
AR (1) AR082621A1 (es)
AU (1) AU2011288533A1 (es)
BR (1) BR112013002985A2 (es)
CA (1) CA2807979A1 (es)
CL (1) CL2013000420A1 (es)
CO (1) CO6690757A2 (es)
CR (1) CR20130059A (es)
DO (1) DOP2013000035A (es)
EC (1) ECSP13012434A (es)
GT (1) GT201300038A (es)
MA (1) MA34464B1 (es)
MX (1) MX2013001647A (es)
PE (1) PE20131326A1 (es)
RU (1) RU2013110525A (es)
SG (1) SG187791A1 (es)
TW (1) TW201221504A (es)
UY (1) UY33552A (es)
WO (1) WO2012019967A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2631320C2 (ru) 2011-12-06 2017-09-21 Санофи Кристаллические формы [(s)-1-карбамоил-2-(фенилпиримидин-2-иламино)этил]амида 2-(2-метиламинопиримидин-4-ил)-1н-индол-5-карбоновой кислоты

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19850301A1 (de) * 1998-10-30 2000-05-04 Basf Ag Verfahren zur Racematspaltung von 2-Hydroxypropionsäuren
DE19951360A1 (de) 1999-10-26 2001-05-03 Aventis Pharma Gmbh Substituierte Indole
US7462638B2 (en) 2002-08-17 2008-12-09 Sanofi-Aventis Deutschland Gmbh Use of IκB-kinase inhibitors in pain therapy
DE10237722A1 (de) 2002-08-17 2004-08-19 Aventis Pharma Deutschland Gmbh Indol- oder Benzimidazolderivate zur Modulation der IKappaB-Kinase
DE102004033406A1 (de) * 2004-07-10 2006-02-16 Sanofi-Aventis Deutschland Gmbh Verfahren zur Herstellung der enantiomeren Formen von 2,3-Diaminopropionsäurederivaten
US20070142417A1 (en) * 2005-05-11 2007-06-21 Aventis Pharmaceuticals Inc Substantially Pure 2-{[2-(2-Methylamino-Pyrimidin-4-YL)-1H-Indole-5-Carbonyl]-Amino}-3-Phenylpyridin-2-YL-Amino)-Propionic Acid as an IkB Kinase Inhibitor
DE102005025225A1 (de) 2005-06-01 2006-12-07 Sanofi-Aventis Deutschland Gmbh Verfahren zur Herstellung von 2-(2-Amino-pyrimidin-4-yl)-1H-indol-5-carbonsäure-derivaten

Also Published As

Publication number Publication date
ECSP13012434A (es) 2013-03-28
AR082621A1 (es) 2012-12-19
CN103209961A (zh) 2013-07-17
MX2013001647A (es) 2013-03-21
AU2011288533A1 (en) 2013-02-28
MA34464B1 (fr) 2013-08-01
CO6690757A2 (es) 2013-06-17
CA2807979A1 (en) 2012-02-16
US8877926B2 (en) 2014-11-04
US20130211085A1 (en) 2013-08-15
GT201300038A (es) 2015-06-24
DOP2013000035A (es) 2013-03-15
SG187791A1 (en) 2013-03-28
RU2013110525A (ru) 2014-09-20
BR112013002985A2 (pt) 2017-11-07
KR20130099044A (ko) 2013-09-05
UY33552A (es) 2012-03-30
CL2013000420A1 (es) 2013-04-05
WO2012019967A1 (en) 2012-02-16
US9434696B2 (en) 2016-09-06
PE20131326A1 (es) 2013-11-12
TW201221504A (en) 2012-06-01
EP2603491B1 (en) 2014-09-24
EP2603491A1 (en) 2013-06-19
JP6000248B2 (ja) 2016-09-28
US20150018554A1 (en) 2015-01-15
JP2013533296A (ja) 2013-08-22

Similar Documents

Publication Publication Date Title
CR20160119A (es) Nuevos compuestos y sus composiciones farmacéuticas para el tratamiento de la fibrosis quística
ECSP13012958A (es) Inhibidores de benzodioxano de la producción de leucotrieno.
UY36735A (es) Nuevos derivados hidroxiácido, un proceso para su preparación y composiciones farmacéuticas que los contienen
CR20150370A (es) Compuestos antivirales
UY34104A (es) ?compuestos derivados benzamídicos heterocíclicos, procesos e intermedios para su preparación, composiciones y métodos para su uso?.
ECSP13012612A (es) Derivados de quinazolin-4-(3h)-ona utilizados como inhibidores de p13 cinasa
CR20140275A (es) Triazolopiridinas sustituidas
IN2015KN00262A (es)
UY33943A (es) Derivados espirocíclicos de isoxazolina como agentes antiparasitarios.
ECSP13013008A (es) Imidazopiridazinas como inhibidores de quinasa akt
CR20140200A (es) Formas solidas de 3-(5-amino-2-metil-4-oxo-ah-quinazolin-3-il)-piperidin-2,6-diona, y sus composiciones farmaceuticas y sus usos
UY33735A (es) Compuestos antivirales
ECSP11011079A (es) Nuevos compuestos de hidroxiareno.
CO2017008600A2 (es) Análogos de desacetoxitubulisina h, composiciones y método de producción de los mismos
BR112013000248A2 (pt) derivados de dióxido de 1,3-propano espirociclicamente substituído, método para a produção dos mesmos e uso dos mesmos como medicamento
BR112013019520A2 (pt) método para produção de 2,3-butanodiol por fermentação
CL2007003671A1 (es) Metodo para la preparacion de derivados del acido 2-amino-5-cianobenzoico, utiles como intermediarios para la preparacion de las correspondientes diamidas cianoantranilicas.
BR112012030742A2 (pt) ésteres de dialcanolamina quaternários
ECSP099070A (es) Bencilaminas, un proceso para su producción y su uso como agentes anti-inflamatorios
CL2011000296A1 (es) Proceso de preparación del ester metílico del ácido 4-oxo-octahidro-indol-1-carboxílico y compuestos intermediarios utilizados.
BR112013011417A2 (pt) microrganismos para a produção de 1,3-propanodiol usando alta concentração de glicerina
BR112012030412A2 (pt) ésteres de dialcanolamina quaternários
WO2013006734A8 (en) Substituted 4-phenoxyphenol analogs as modulators of proliferating cell nuclear antigen activity
UY34612A (es) ?procedimiento para la preparación de derivados de isoxazolina azetidina quirales como agentes antiparasitarios?.
ECSP13012548A (es) Inhibidores de oxadiazol de la producción de leucotrienos.